SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 28, 2004
Eyetech Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50516 13-4104684
- ---------------------------- ------------- -------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Numbers) Identification No.)
500 Seventh Avenue, 18th Floor
New York, NY 10018
- ---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (212) 997-9241
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 9. Regulation FD Disclosure
On Saturday, February 28, 2004, the results from the VEGF Inhibition
Study in Ocular Neovascularization (VISION) were presented at the 27th annual
Macula Society meeting. The study was sponsored by Eyetech Pharmaceuticals,
Inc. and Pfizer Inc. The full text of the trade release issued in connection
with the presentation of the study is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: March 2, 2004 EYETECH PHARMACEUTICALS, INC.
By: /s/ Glenn Sblendorio
--------------------
Name: Glenn P. Sblendorio
Title: Senior Vice President, Finance and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Trade release dated March 2, 2004